COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva.
COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva.
复制标题
DOI：
10.1128/jcm.02204-20
复制
发表时间：
2020-12-17
影响因子：
9.4
通讯作者：
Heaney CD
中科院分区：
文献类型：
--
作者：
Pisanic N;Randad PR;Kruczynski K;Manabe YC;Thomas DL;Pekosz A;Klein SL;Betenbaugh MJ;Clarke WA;Laeyendecker O;Caturegli PP;Larman HB;Detrick B;Fairley JK;Sherman AC;Rouphael N;Edupuganti S;Granger DA;Granger SW;Collins MH;Heaney CD
严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）是一种持续流行的原因，已感染3600多万人，造成100多万人死亡。政府公共卫生政策的知情实施取决于在人口规模上SARS-CoV-2免疫力的准确数据。我们假设SARS-CoV-2唾液抗体检测可以作为血清学检测的非侵入性替代方法，用于监测人群规模的SARS-CoV-2感染和血清阳性。严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）是一种持续流行的原因，已感染3600多万人，造成100多万人死亡。政府公共卫生政策的知情实施取决于在人口规模上SARS-CoV-2免疫力的准确数据。我们假设SARS-CoV-2唾液抗体检测可以作为血清学检测的非侵入性替代方法，用于监测人群规模的SARS-CoV-2感染和血清阳性。我们基于Luminex技术建立了一种多重SARS-CoV-2抗体免疫分析方法，该方法包含12种CoV抗原，主要来自SARS-CoV-2核衣壳（N）和刺突（S）。从确诊的2019冠状病毒病（COVID-19）病例和前COVID-19时代收集的唾液和血清进行了IgG、伊加和IgM抗原检测。匹配的唾液和血清IgG应答（n = 28）显著相关。唾液抗N IgG应答导致最高灵敏度（100%），在症状发作后>14天（DPSO）采样的24/24例逆转录PCR（RT-PCR）确认的COVID-19病例中显示阳性应答，而唾液抗受体结合域（RBD）IgG应答产生100%特异性。唾液中IgG的时间动力学与血液中观察到的一致，表明大多数个体在10 DPSO左右发生血清转化。采用对N和S抗原的IgG应答的组合的算法导致早至10 DPSO的高诊断准确性（100%）。这些结果支持使用唾液为基础的抗体检测作为一种非侵入性和可扩展的替代血液为基础的抗体检测。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pandemic that has infected over 36 million and killed over 1 million people. Informed implementation of government public health policies depends on accurate data on SARS-CoV-2 immunity at a population scale. We hypothesized that detection of SARS-CoV-2 salivary antibodies could serve as a noninvasive alternative to serological testing for monitoring of SARS-CoV-2 infection and seropositivity at a population scale. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pandemic that has infected over 36 million and killed over 1 million people. Informed implementation of government public health policies depends on accurate data on SARS-CoV-2 immunity at a population scale. We hypothesized that detection of SARS-CoV-2 salivary antibodies could serve as a noninvasive alternative to serological testing for monitoring of SARS-CoV-2 infection and seropositivity at a population scale. We developed a multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology that comprised 12 CoV antigens, mostly derived from SARS-CoV-2 nucleocapsid (N) and spike (S). Saliva and sera collected from confirmed coronavirus disease 2019 (COVID-19) cases and from the pre-COVID-19 era were tested for IgG, IgA, and IgM to the antigen panel. Matched saliva and serum IgG responses (n = 28) were significantly correlated. The salivary anti-N IgG response resulted in the highest sensitivity (100%), exhibiting a positive response in 24/24 reverse transcription-PCR (RT-PCR)-confirmed COVID-19 cases sampled at >14 days post-symptom onset (DPSO), whereas the salivary anti-receptor binding domain (RBD) IgG response yielded 100% specificity. Temporal kinetics of IgG in saliva were consistent with those observed in blood and indicated that most individuals seroconvert at around 10 DPSO. Algorithms employing a combination of the IgG responses to N and S antigens result in high diagnostic accuracy (100%) by as early as 10 DPSO. These results support the use of saliva-based antibody testing as a noninvasive and scalable alternative to blood-based antibody testing.